Coherex Medical was founded in 2003 to design, develop and market innovative catheter-based technologies for the treatment of certain structural heart defects. The first device designed by the company was the Coherex FlatStent® EF Patent Foramen Ovale (PFO) closure device, which was the first device featuring the benefits of in-tunnel PFO closure to receive CE mark.
In 2009 the company refocused its research & development efforts on a novel left atrial appendage occluder. In November of 2010 the Coherex WaveCrest® LAA occlusion system initiated clinical trials in Europe and Australia/New Zealand. Today the Coherex WaveCrest occluder is CE marked and available for implant in the applicable countries. In September, 2013 Coherex Medical announced a strategic partnership with Biosense-Webster, an industry leader in developing treatment options for patients with atrial fibrillation, for exclusive distribution of the Coherex WaveCrest LAA Occlusion System in key markets outside the United States.
Coherex Medical continues to focus on further clinical trials to expand the development and adoption of novel structural heart devices.